Drugs / Benaglutide
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05226000 | Jul → Dec 2020 | — | The Affiliated Hospital of Qingdao University | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03986008 | Dec 2019 → Dec 2021 | obesity disorder | Xiangya Hospital of Central South University | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07687667 | Jul 2026 → Dec 2028 expected | female infertility, obesity disorder, polycystic ovary syndrome | Peking University Third Hospital | Not yet recruiting | No outcome recorded |
| — | NCT06775093 | Mar 2025 → Dec 2026 expected | female infertility, obesity disorder, polycystic ovary syndrome | Peking University Third Hospital | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03593668 Comparator | Dec 2017 → Oct 2019 | obesity disorder | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Benaglutide | “Benaglutide injection (Fisuomei®, National Medicine Standard No. S20230042, Shanghai Renhui Biopharmaceutical Co., Ltd.) was administered at an initial dose of 0.06 mg per...” NCT07687667 ↗5“Benaglutide injection (Fisuomei®, National Medicine Standard No. S20230042, Shanghai Renhui Biopharmaceutical Co., Ltd.)” NCT06775093 ↗ “Benaglutide” NCT06775093 ↗ |
| Known as | Fisuomei | “Benaglutide injection (Fisuomei®, National Medicine Standard No. S20230042, Shanghai Renhui Biopharmaceutical Co., Ltd.) was administered at an initial dose of 0.06 mg per...” NCT07687667 ↗1“Benaglutide injection (Fisuomei®, National Medicine Standard No. S20230042, Shanghai Renhui Biopharmaceutical Co., Ltd.)” NCT06775093 ↗ |
| Action | Activate | “GLP-1 receptor agonist” NCT06775093 ↗ |
| Route | Subcutaneous | “by subcutaneous injection (under the skin)” NCT03986008 ↗ |